Proving Nose-to-Brain Transport: Tracers, CSF Sampling and the Two Percentages Everyone Quotes

The claim that a compound reaches the brain “directly from the nose” appears in a great many papers. It is a seductive idea: the olfactory nerve endings in the roof of the nasal cavity are in contact with the outside world on one side and the brain on the other, with no blood-brain barrier in the way along that route. But claiming a route and proving it are different things, and the methods that researchers use to separate direct transport from ordinary absorption are worth understanding if you want to read this literature critically.

The problem: everything gets into the blood too

When you put a liquid in a rodent’s nose, three things can happen at once.

1. Some of it is absorbed across the nasal mucosa into the bloodstream, from which it can reach the brain by crossing the blood-brain barrier like any other systemic compound.
2. Some of it travels along olfactory or trigeminal nerve pathways or the spaces around them, reaching the olfactory bulb, brainstem or cerebrospinal fluid without passing through the blood first.
3. A large amount is swallowed, because the nasal cavity drains to the throat. This material goes through the gut.

If you measure the compound in the brain afterward, you cannot tell which route delivered it. Every serious study therefore has to include a comparison that isolates the direct pathway.

The standard design: intranasal versus intravenous

The classic approach is to give the same compound to two groups of animals, one intranasally and one intravenously, and compare brain and blood concentrations over time. If the nasal route produces relatively more in the brain for the amount that reaches the blood, that is evidence for direct transport.

Two derived numbers are commonly reported.

Drug targeting efficiency (DTE%). This compares the brain-to-blood exposure ratio after intranasal dosing with the same ratio after intravenous dosing:

DTE% = [(AUC brain / AUC blood) intranasal ÷ (AUC brain / AUC blood) intravenous] × 100

A value above 100 percent suggests that the nasal route delivers more to the brain relative to the blood than a purely intravenous route does.

Direct transport percentage (DTP%). This estimates what fraction of the brain exposure after intranasal dosing is attributable to direct nose-to-brain transport, by subtracting the portion that would be expected from blood-borne delivery alone.

Both are derived from area-under-the-curve (AUC) values, so they depend on how many time points were sampled, how the animals were dosed and how well the measurements were made.

Why those percentages deserve skepticism

DTE% and DTP% are easy to compute and easy to over-interpret. A few reasons for care:

• Small numbers of animals per time point. Brain concentration requires euthanizing the animal, so each time point uses different animals. Sparse sampling produces noisy AUC values.
• Blood contamination of brain tissue. The brain contains blood. If the compound is abundant in blood, residual blood in the tissue sample inflates the brain measurement. Perfusing the animal with saline before harvest reduces this but is not always done.
• Regional variation. The olfactory bulb often shows high levels, while deeper regions show little. A whole-brain average can hide that gradient or mislead.
• Different clearance routes. The compound may be removed from brain and blood at different rates after the two routes, which changes the ratios independent of transport.
• Unequal systemic exposure. If intranasal dosing gives much lower blood levels than intravenous dosing, a high brain-to-blood ratio can arise just from the denominator being small.

Tracer studies: seeing the route

To complement concentration data, researchers use tracers that can be located directly.

• Fluorescent or radiolabeled molecules. A labeled peptide or a surrogate such as fluorescent dextran can be imaged in brain sections, showing whether it appears along the olfactory nerve and in the olfactory bulb.
• Autoradiography and PET. Radiolabeled compounds can be mapped across the brain, and in larger animals, imaged noninvasively.
• Time-resolved sampling. Direct transport along nerve pathways is thought to be fast, with compounds sometimes detected in the olfactory bulb or cerebrospinal fluid within minutes. Blood-borne delivery usually lags. The timing profile is itself informative.
• Cerebrospinal fluid sampling. In rats, fluid can be collected from the cisterna magna to measure the compound directly, bypassing brain homogenization.
• Blocking experiments. Temporarily impairing the olfactory epithelium (with a chemical lesion, for example) and showing that brain delivery drops supports a role for the olfactory pathway.

The practical issues of dosing a small nose

Volumes are tiny. A rodent nostril accommodates only microliters, and a liquid delivered too quickly runs down the throat. Common refinements include dosing in small aliquots alternated between nostrils, positioning the animal so the liquid stays in the nasal cavity, and using light anesthesia to prevent sneezing and grooming. Each of these changes the result, so a methods section that omits them is hard to reproduce.

What this means for peptide researchers

When a paper reports that an intranasal peptide produces a brain effect, the best questions to ask are:

1. Was there an intravenous comparison arm?
2. Were brain concentrations measured, or only a downstream effect?
3. Was blood perfused out of the brain before analysis?
4. Is the analytical method specific for the intact peptide, rather than fragments?
5. Were the animals’ swallowing and systemic exposure accounted for?

A study that answers these is considerably more persuasive than one that observes a behavioral change and infers a pathway.

Researchers designing intranasal work with Semax can review specifications and batch documentation on the Nasal Semax product page.

All Lucid Aminos products are sold strictly for laboratory research use. They are not drugs, dietary supplements or food, and they are not for human or veterinary use. This article is educational, describes published research methods, and is not medical advice.